Barriers to intravenous penicillin use for treatment of nonmeningitis pneumococcal disease

Journal of Clinical Microbiology

Volumn 48, Issue 9, 2010, Pages 3372-3374

  Rosen, Jennifer ^a   Beekmann, Susan ^b   Polgreen, Philip ^b   Moore, Matthew ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENICILLIN G;

ANTIBIOTIC THERAPY; ARTICLE; ASTHMA; AWARENESS; CLINICAL ASSESSMENT; CONSENSUS DEVELOPMENT; DESCRIPTIVE RESEARCH; FRIEND; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; NORMAL HUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PUBLICATION; QUESTIONNAIRE; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INJECTIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; PENICILLINS; PHYSICIANS; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 77956802515     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01012-10     Document Type: Article

References (7)

1. Andes, D. 2001. Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections. Curr. Opin. Infect. Dis. 14:165-172.
2. Centers for Disease Control and Prevention. 2008. Effects of new penicillin susceptibility breakpoints for Streptococcus pneumoniae - United States, 2006-2007. MMWR Morb. Mortal. Wkly. Rep. 57:1353-1355.
3. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. Approved standard M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Dellit, T. H., R. C. Owens, J. E. McGowan, Jr., D. N. Gerding, R. A. Weinstein, J. P. Burke, W. C. Huskins, D. L. Paterson, N. O. Fishman, C. F. Carpenter, P. J. Brennan, M. Billeter, and T. M. Hooton. 2007. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis. 44:159-177.
5. Infections Diseases Society of America. 2008. Penicillin's back: FDA raises breakpoints for S. pneumoniae pneumonia. IDSA News 18(4). http://www.idsociety.org/newsArticle.aspx?id=11010.
6. MacDougall, C., J. P. Powell, C. K. Johnson, M. B. Edmond, and R. E. Polk. 2005. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin. Infect. Dis. 41:435-440.
7. Weinstein, M. P., K. P. Klugman, and R. N. Jones. 2009. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin. Infect. Dis. 48:1596-1600.